| Literature DB >> 32715344 |
Zan Zhang1, Hai-Bin Huang1, Yan-Long Jiang1, Jing Liu1, Xing Gao1, Yang Liu1, Wen-Tao Yang1, Chun-Wei Shi1, Dan Wang1, Jian-Zhong Wang1, Yuan-Huan Kang1, Chun-Feng Wang2, Gui-Lian Yang3.
Abstract
Chicken coccidiosis is a protozoan parasitic disease that leads to considerable economic losses in the poultry industry. In this study, we used invasive Lactobacillus plantarum (L.P) expressing the FnBPA protein as a novel bacterial carrier for DNA delivery into epithelial cells to develop a live oral DNA vaccine. A fusion DNA vaccine co-expressing EtMIC2 and chicken IL-18 (chIL-18) was constructed and then delivered to the host by invasive L.P. Its efficacy against Eimeria tenella challenge was evaluated in chickens by examining the relative weight gain rate; caecal lesion score; OPG; anti-coccidial index (ACI); levels of EtMIC2 antibody, FnBPA, IL-4, IL-18, IFN-γ and SIgA; and proliferation ability and percentages of CD4+ and CD8+ splenocytes. The experimental results showed that chickens immunized with invasive L.P carrying the eukaryotic expression vector pValac-EtMIC2 (pValac-EtMIC2/pSIP409-FnBPA) had markedly improved immune protection against challenge compared with that of chickens immunized with non-invasive L.P (pValac-EtMIC2/pSIP409). However, invasive L.P co-expressing EtMIC2 with the chIL-18 vector exhibited the highest protection efficiency against E. tenella. These results indicate that invasive Lactobacillus-expressing FnBPA improved humoural and cellular immunity and enhanced resistance to E. tenella. The DNA vaccine delivered by invasive Lactobacillus provides a new concept and method for the prevention of E. tenella.Entities:
Keywords: Coccidiosis; DNA delivery; EtMIC2; Invasive Lactobacillus plantarum; chIL-18
Mesh:
Substances:
Year: 2020 PMID: 32715344 PMCID: PMC7382971 DOI: 10.1007/s00436-020-06745-w
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.289
Bacterial strains, plasmids and primers used in this work
| Strains | Characteristics and plasmids | Reference |
|---|---|---|
| Non-invasive | Em, pSIP409 | Lab source |
| Invasive L. plantarum NC8 | Em, pSIP409-FnBPA | Lab source |
| Cm, pValac | TaKaRa Corporation, Japan | |
| pValac/pSIP409 | Em, Cm, double plasmids | This work |
| pValac-EtMIC2/pSIP409 | Em, Cm, double plasmids | This work |
| pValac-EtMIC2/pSIP409-FnBPA | Em, Cm, double plasmids | This work |
| pValac-EtMIC2-IL18/pSIP409 | Em, Cm, double plasmids | This work |
| pValac-EtMIC2-IL18/pSIP409-FnBPA | Em, Cm, double plasmids | This work |
Fig. 1Vectors and Western blot. The genes encoding EtMIC2 and EtMIC2-IL18 were inserted into the vector pValac, yielding pValac-EtMIC2 (a) and pValac-EtMIC2-IL18 (b), respectively. The expression of EtMIC2 and EtMIC2-IL18 was confirmed by Western blotting using anti-Flag tag (c) and anti-His tag monoclonal antibodies (d) as primary antibodies and HRP-conjugated goat anti-mouse IgG as the secondary antibody. Lane 1, protein marker; Lane 2, pValac without EtMIC2 and IL18 production; Lane 3 and Lane 4, EtMIC2 and IL-18 proteins expressed in 293T cells transfected with pValac-EtMIC2 and pValac-EtMIC2-IL18, respectively
Experimental groups of chickens in immunization and challenge experiment
| Groups | Strains | Immunization (dose) | Challenge(dose) |
|---|---|---|---|
| I | / | Normal saline/0.2 mL | / |
| II | / | Normal saline/0.2 mL | 5.0 × 104/0.5 mL |
| III | pValac/pSIP409 | 1.0 × 109 CFU/0.2 mL | 5.0 × 104/0.5 mL |
| IV | pValac-EtMIC2/pSIP409 | 1.0 × 109 CFU/0.2 mL | 5.0 × 104/0.5 mL |
| V | pValac-EtMIC2/pSIP409-FnBPA | 1.0 × 109 CFU/0.2 mL | 5.0 × 104/0.5 mL |
| VI | pValac-EtMIC2-IL18/pSIP409-FnBPA | 1.0 × 109 CFU/0.2 mL | 5.0 × 104/0.5 mL |
Fig. 2Indirect immunofluorescence. IFA detection of the EtMIC2 and IL-18 proteins expressed in 293T cells transfected with recombinant plasmids. a pValac without EtMIC2- and IL18-producing transfected cells was used as the negative control. b pValac with EGFP-producing transfected cells as the positive control. c pValac-EtMIC2-transfected cells were stained with DAPI, an anti-Flag tag monoclonal antibody and FITC-conjugated goat anti-mouse IgG. d pValac-EtMIC2-IL18-transfected cells were stained with DAPI, an anti-Flag tag monoclonal antibody and FITC-conjugated goat anti-mouse IgG. e pValac-EtMIC2-IL18-transfected cells were stained with DAPI, an anti-His tag monoclonal antibody and FITC-conjugated goat anti-mouse IgG. Arrows indicate the expression of the target protein in 293T cells
Fig. 3Growth curves and CEF invasion test. a Growth curves of the 4 strains and b determination of the invasion rates of the recombinant strains in vitro. By stimulating CEFs and counting the number of intracellular bacteria, the cell invasion rates were calculated. Statistically, P < 0.001 was statistically significant and marked as triple asterisks
Fig. 4ELISA test. a The specific antibody EtMIC2 levels of chickens in six groups at 30 days and 38 days. b Detection of IFN-γ levels in the serum of chickens at 30 days. c Detection of IL-4 levels in the serum of chickens at 30 days. d Detection of IL-18 levels in the serum of chickens at 30 days. e Assay of SIgA in the intestinal lavage fluid of chickens at 30 days. f Detection results of the FnBPA antibody in the serum at 30 days. (*P < 0.05, **P < 0.01 and ***P < 0.001)
Fig. 5Lymphocyte proliferation and increased rates of CD3+CD4+ and CD3+CD8+ T cells. a Single cells were prepared from peripheral blood leukocytes (PBLs) as described, followed by stimulation with concanavalin A (10 μg/mL) for approximately 48 h. Evaluation of cell proliferation status by the MTT assay. b The percentage of CD4+ splenocytes was determined at 30 days and 38 days by FACS. c The percentage of CD8+ splenocytes was determined at 30 days and 38 days by FACS. (*P < 0.05, **P < 0.01 and ***P < 0.001)
Fig. 6Protection against E. tenella challenge by all recombinant L.P strains. a The chicken RWG values were measured 8 days post-challenge. b The LS values were recorded until 8 days post-challenge and calculated. c Statistics of OPG values. d The caeca were collected and evaluated by histopathologic analysis. (*P < 0.05, **P < 0.01 and ***P < 0.001)
Anticoccidiosis index
| Groups | Relative weight gain rate (%) | The survival rate (%) | Oocyst value | Pathological change value | ACI |
|---|---|---|---|---|---|
| Group I | 100 | 100 | 0 | 0 | 200 |
| Group II | 55.93 | 100 | 10 | 29 | 116.93 |
| Group III | 71.19 | 100 | 10 | 20 | 141.19 |
| Group IV | 76.27 | 100 | 1 | 13 | 162.27 |
| Group V | 79.66 | 100 | 1 | 11 | 167.66 |
| Group VI | 84.75 | 100 | 1 | 9 | 174.75 |